5879 Results for "

Non-

" in MedChemExpress (MCE) Product Catalog:
Products (5879)

5879 Results for "Non-" in MCE Product Catalog:

52
52 Cited Publications
Cat. No.: HY-15947
CAS No.: 1453848-26-4
Synonyms: GDC-0994
Research Areas:  

Cancer

Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-15947A
CAS No.: 2070009-58-2
Synonyms: GDC-0994 hydrochloride
Research Areas:  

Cancer

Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally active ERK1/2 inhibitor. Ravoxertinib hydrochloride inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib hydrochloride decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib hydrochloride can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
loading...
    loading...
49
49 Cited Publications
Cat. No.: HY-13813
CAS No.: 674289-55-5
Purity:  98.89%
Target:  

Myosin

Research Areas:  

Others

Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function. Blebbistatin blocks cell migration .
loading...
    loading...
47
47 Cited Publications
Cat. No.: HY-10095
CAS No.: 204697-65-4
Purity:  99.83%
Synonyms: BIBN-4096; BIBN 4096BS
Target:  

CGRP Receptor

Research Areas:  

Neurological Disease

Olcegepant (BIBN-4096) is a potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with IC50 of 0.03 nM and Ki of 14.4 pM for human CGRP .
loading...
    loading...
47
47 Cited Publications
Cat. No.: HY-10095A
CAS No.: 586368-06-1
Purity:  99.11%
Synonyms: BIBN-4096 hydrochloride; BIBN4096BS hydrochloride
Target:  

CGRP Receptor

Research Areas:  

Neurological Disease

Olcegepant hydrochloride (BIBN-4096 hydrochloride) is a potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with IC50 of 0.03 nM and with a Ki of 14.4 pM for human CGRP .
loading...
    loading...
44
44 Cited Publications
Cat. No.: HY-13062
CAS No.: 23541-50-6
Purity:  99.67%
Synonyms: Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride
Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .
loading...
    loading...
44
44 Cited Publications
Cat. No.: HY-13062A
CAS No.: 20830-81-3
Synonyms: Daunomycin; RP 13057; Rubidomycin
Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .
loading...
    loading...
41
41 Cited Publications
Cat. No.: HY-12497
CAS No.: 219766-25-3
Purity:  99.90%
ANA-12 is a brain-penetrant, selective TrkB antagonist with IC50 values of 45.6 nM and 41.1 μM, and Kd values of 10 nM and 12 μM, for high- and low-affinity sites, respectively. ANA-12 specifically inhibits BDNF-induced TrkB receptor activation and its downstream signaling cascades by directly and non-competitively binding to the TrkB receptor, without affecting the functions of TrkA and TrkC. ANA-12 is used in research concerning neuropsychiatric disorders (such as depression and anxiety), acute and chronic pain, neuroimmune inflammation, and the mechanisms of learning and memory .
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-112288
CAS No.: 432001-19-9
Purity:  99.90%
Synonyms: TTI-101
C188-9 (TTI-101) is a STAT3 inhibitor with a Kd value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia .
loading...
    loading...
36
36 Cited Publications
Cat. No.: HY-12755
CAS No.: 71203-35-5
Purity:  99.96%
Synonyms: CID-2950007
Target:  

Ras Apoptosis

Research Areas:  

Cancer

ML141 (CID-2950007) is a potent, allosteric, selective and reversible non-competitive inhibitor of Cdc42 GTPase. ML141 inhibits Cdc42 wild type and Cdc42 Q61L mutant with EC50s of 2.1 and 2.6 μM, respectively. ML141 shows low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 do not show cytotoxicity in multiple cell lines .
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-136927
CAS No.: 129425-81-6
Purity:  99.81%
Target:  

STING

Research Areas:  

Inflammation/Immunology Cancer

MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-131454
CAS No.: 2375421-09-1
Purity:  99.89%
Target:  

STING

Research Areas:  

Inflammation/Immunology Cancer

SR-717 is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-131454A
CAS No.: 2375420-34-9
Purity:  98.05%
Target:  

STING

Research Areas:  

Inflammation/Immunology Cancer

SR-717 free acid is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 free acid is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-101966
CAS No.: 1916571-90-8
Purity:  99.69%
NCT-503 is a blood-brain barrier-permeable, non-competitive PHGDH inhibitor with an IC50 of 2.5 μM against human PHGDH. NCT-503 reduces glucose-derived serine production and the incorporation of one-carbon units into nucleotides without decreasing PHGDH protein expression. NCT-503 prevents high selenium-induced insulin resistance in mice by regulating blood glucose and insulin levels and improving glucose tolerance, and also inhibits the growth of tumors overexpressing PHGDH. NCT-503 can be used in research related to insulin resistance and breast cancer .
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-103490
CAS No.: 1111556-37-6
Purity:  99.41%
Synonyms: EDHS-206
Target:  

MAP3K Apoptosis

Takinib (EDHS-206) is an orally active and selective TAK1 inhibitor (IC50=9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib is an inhibitor of autophosphorylated TAK1 that non-competitively binds within the ATP binding pocket. Takinib induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is also a P. falciparum protein kinase 9 (PfPK9) inhibitor (KD(app) of 0.46 μM) .
loading...
    loading...
31
31 Cited Publications
Cat. No.: HY-N0390
CAS No.: 56-85-9
Synonyms: L-Glutamic acid 5-amide
L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells .
loading...
    loading...
30
30 Cited Publications
Cat. No.: HY-118263
CAS No.: 1042385-75-0
Purity:  99.03%
Synonyms: PF-00299804 hydrate; PF-299804 hydrate
Target:  

EGFR

Research Areas:  

Cancer

Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC) .
loading...
    loading...
30
30 Cited Publications
Cat. No.: HY-Y1883
CAS No.: 9002-93-1
Research Areas:  

Infection Cancer

Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is a non-denaturing detergent that solubilizes lipid membranes. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is commonly used in laboratories and is applied to vaccines at different stages of the manufacturing process. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is listed as an excipient in certain vaccines including split virus influenza vaccines. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is a nonionic surfactant. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant induces Apoptosis in prostate and colon cancer cell lines and reduces the infectivity of classic enveloped viruses such as WNV .
loading...
    loading...
30
30 Cited Publications
Cat. No.: HY-Y1883A
CAS No.: 9002-93-1
Research Areas:  

Infection Cancer

Polyethylene glycol mono(4-tert-octylphenyl) ether is a non-denaturing detergent that solubilizes lipid membranes. Polyethylene glycol mono(4-tert-octylphenyl) ether is commonly used in laboratories and is applied to vaccines at different stages of the manufacturing process. Polyethylene glycol mono(4-tert-octylphenyl) ether is listed as an excipient in certain vaccines including split virus influenza vaccines. Polyethylene glycol mono(4-tert-octylphenyl) ether is a nonionic surfactant. Polyethylene glycol mono(4-tert-octylphenyl) ether induces Apoptosis in prostate and colon cancer cell lines and reduces the infectivity of classic enveloped viruses such as WNV .
loading...
    loading...
29
29 Cited Publications
Cat. No.: HY-13441
CAS No.: 856925-71-8
Purity:  99.42%
Target:  

Myosin

Research Areas:  

Cardiovascular Disease Cancer

(-)-Blebbistatin is a selective inhibitor of the ATPase activity of non-muscle myosin II .
loading...
    loading...